### PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHOR	ITY	"ANS!		
To:			PCT PCT	
		•	RITTEN OPINION OF THE TONAL SEARCHING AUTHORITY	
,			(PCT Rule 43bis.1)	
		Date of mailing (day/month/year)		
Applicant's or agent's file reference ITR04002	· · · · · · · · · · · · · · · · · · ·	FOR FURTHER	ACTION See paragraph 2 below	
International application No. PCT/JP2005/000171	International filing date (	(day/month/year)	Priority date (day/month/year) 08.01.2004	
International Patent Classification (IPC) or both	n national classification an	d IPC		
Applican ITO, Kohzo				
Box No. IV Lack of unit  Box No. V Reasoned st applicability  Box No. VI Certain doct  Box No. VII Certain defe  Box No. VIII Certain obse  2. FURTHER ACTION  If a demand for international prelin International Preliminary Examining than this one to be the IPEA and the this International Searching Authority If this opinion is, as provided above,	opinion  shment of opinion with regression of the principle of invention at a considered sets in the international approximation on the internation of the internation of the principle of the pr	gard to novelty, invent  I(a)(i) with regard to  ns supporting such state  plication  nal application  ade, this opinion with that this does not applicate the expiration  on opinion of the IPE/  before the expiration	Il be considered to be a written opinion of the ply where the applicant chooses an Authority other eau under Rule 66.1 bis(b) that written opinions of A, the applicant is invited to submit to the IPEA a of 3 months from the date of mailing of Form	
Name and mailing address of the ISA/JP	,	Authorized officer		
Facsimile No.		Telephone No.		

B	ox No. I	Basis of this opinion	
Γ.	. With	regard to the language, this opinion has been established on the basis of the international application in the language in which it wa unless otherwise indicated under this item.	s
		This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under	•
	-	Rule 12.3 and 23.1(b)).	
2.		regard to any nucleotide and/or umino acid sequence disclosed in the international application and necessary to the claimention, this opinion has been established on the basis of:	d
	a.	type of material	
		a sequence listing	
		table(s) related to the sequence listing	
	b.	format of material	
		in written format	
		in computer readable form	
	c.	time of filing/furnishing	
		contained in the international application as filed.	
		filed together with the international application in computer readable form.	
		furnished subsequently to this Authority for the purposes of search.	
3		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed of furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	or is
4	. Add	itional comments:	

International application No.
PCT/JP2005/000171

Box			ale 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; poorting such statement	
1.	Statement			
	Novelty (N)	Claims	2-11	YES
		Claims	1, 12-29	NO
	Inventive step (IS)	Claims	2-11	YES
		Claims	1, 12-29	NO
	Industrial applicability (IA)	Claims	1-29	YES
		Claims		NO

#### 2. Citations and explanations:

- The inventions of claims 1 and 12-22 do not appear to possess novelty or to involve an inventive step.

Document 1: WO 2002/002159 A1 (Japan Tissue Engineering Co Lt), 10 January 2002, claims, page 8, lines 2-8, page 11, line 12 to page 15, line 25, Fig. 2

Document 2: Takahiro ICHI et al., Polyrotaxane o kihon kokkaku to shita 3-jigen soshikitai no chousei to sono tokusei kaiseki, Japan Society of Mechanical Engineers, Dai 12-kai Bioengineering Koenkai - Shinseiki ni okeru bioengineering no yakuwari o kangaeru - Koen Ronbunshu, 05 January 2000, pp. 217-218

Document 3: WO 2001/083566 A1 (Center Advanced Science & Technology, Incubation Center), 08 November 2001, claims, page 19, lines 16-21

Documents 1 and 2 describes a cross-linked polyrotaxane obtained by chemically bonding two or more polyrotaxane molecules through cyclodextrins, wherein part of the hydroxyl group of the cyclodextrin molecules is substituted with N,N'-carboxyl-diimidazole, a cross-linked polyrotaxane is obtained by cross-linking the N,N'-carboxyl-diimidazole substitute group with polyethylene glycol bisamine, etc.

Here, in a case in which the N,N'-carboxyl-diimidazole substitute group is not cross-linked with the polyethylene glycol bisamine and remains, part of the hydroxyl group of the cyclodextrin molecules is substituted with a N,N'-carboxyl-diimidazole group, or in other words, a non-ion group.

Document 3 describes a cross-linked polyrotaxane obtained by chemically bonding two or more polyrotaxane molecules through cyclodextrins, wherein it is preferable to have a thiol group, or in other words, a non-ion group, as the reactive group on the outer side of the cyclodextrin molecules.

Accordingly, there is no difference between the inventions of claims 1 and 12-22 and the inventions described in document 1-3.

- The inventions of claims 23-29 do not appear to possess novelty or to involve an inventive step.

Documents 1 and 2 describe a material constituted from a cross-linked polyrotaxane gel, fürther having water and being in an equilibrium swelling state, etc.

Here, the equilibrium swelling state is a state in which the gel maintains a specific shape, and therefore this examination finds that the cross-linked polyrotaxane gel of documents 1 and 2 can stand on its own.

Box No. VIII Certain observations on the international application			
The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:			
The permeability of the material is specified in claims 25 and 26, but it is unclear what "permeability" is referring to.			
what permeability is referring to.			
•			
*			

Supplemental Box	_
In case the space in any of the preceding boxes is not sufficient.  Continuation of: Box V	
- The inventions of claims 2-11 do not appear to possess novelty or to involve an inventive step.	

### PATENT COOPERATION TREATY

TRANSLATION From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION ITR04002 See paragraph 2 below Priority date (day/month/year) International application No. International filing date (day/month/year) 08.01.2004 PCT/JP2005/000171 11.01.2005 International Patent Classification (IPC) or both national classification and IPC Applicant ITO, Kohzo This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Certain documents cited Box No. VI Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/JP Telephone No.

Facsimile No.

Box	k No. I	Basis of this opinion
1.		regard to the language, this opinion has been established on the basis of the international application in the language in which it was, unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language
		, which is the language of a translation furnished for the purposes of international search (under
		Rule 12.3 and 23.1(b)).
2.		regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed nation, this opinion has been established on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b.	format of material
		in written format
		in computer readable form
	c.	time of filing/furnishing
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Addi	itional comments:
		· ·
		$\cdot$

International application No. PCT/JP2005/000171

	Box No. V Reasoned statement under Rule 43bis.1(a)(l) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
:					
ty (N)	Claims	2-11	YES		
	Claims	1, 12-29	NO		
ive step (IS)	Claims	2-11	YES		
	Claims	1, 12-29	NO		
rial applicability (IA)	Claims	1-29	YES		
	Claims		NO		
i	ive step (IS)	Claims  ive step (IS)  Claims  Claims  Claims  Claims	Claims 1, 12-29  ive step (IS) Claims 2-11 Claims 1, 12-29  rial applicability (IA) Claims 1-29		

#### 2. Citations and explanations:

- The inventions of claims 1 and 12-22 do not appear to possess novelty or to involve an inventive step.

Document 1: WO 2002/002159 A1 (Japan Tissue Engineering Co Lt), 10 January 2002, claims, page 8, lines 2-8, page 11, line 12 to page 15, line 25, Fig. 2

Document 2: Takahiro ICHI et al., Polyrotaxane o kihon kokkaku to shita 3-jigen soshikitai no chousei to sono tokusei kaiseki, Japan Society of Mechanical Engineers, Dai 12-kai Bioengineering Koenkai - Shinseiki ni okeru bioengineering no yakuwari o kangaeru - Koen Ronbunshu, 05 January 2000, pp. 217-218

Document 3: WO 2001/083566 A1 (Center Advanced Science & Technology, Incubation Center), 08 November 2001, claims, page 19, lines 16-21

Documents 1 and 2 describes a cross-linked polyrotaxane obtained by chemically bonding two or more polyrotaxane molecules through cyclodextrins, wherein part of the hydroxyl group of the cyclodextrin molecules is substituted with N,N'-carboxyl-diimidazole, a cross-linked polyrotaxane is obtained by cross-linking the N,N'-carboxyl-diimidazole substitute group with polyethylene glycol bisamine, etc.

Here, in a case in which the N,N'-carboxyl-diimidazole substitute group is not crosslinked with the polyethylene glycol bisamine and remains, part of the hydroxyl group of the cyclodextrin molecules is substituted with a N,N'-carboxyl-diimidazole group, or in other words, a non-ion group.

Document 3 describes a cross-linked polyrotaxane obtained by chemically bonding two or more polyrotaxane molecules through cyclodextrins, wherein it is preferable to have a thiol group, or in other words, a non-ion group, as the reactive group on the outer side of the cyclodextrin molecules.

Accordingly, there is no difference between the inventions of claims 1 and 12-22 and the inventions described in document 1-3.

- The inventions of claims 23-29 do not appear to possess novelty or to involve an inventive step.

Documents 1 and 2 describe a material constituted from a cross-linked polyrotaxane gel, further having water and being in an equilibrium swelling state, etc.

Here, the equilibrium swelling state is a state in which the gel maintains a specific shape, and therefore this examination finds that the cross-linked polyrotaxane gel of documents 1 and 2 can stand on its own.

Box No. VIII	Certain observation	ns on the international ap	plication			
The following of the description,	The following observations on the clarity of the claims, description, and drawing's or on the question whether the claims are fully supported by the description, are made:					
what "	The permeabili permeability" is	ty of the material i	s specified in clain	ns 25 and 26,	but it is unc	lear
Wildt	permeability is	reterring to.		•		
·						
			•			
			•			

the amounts 44	and the house to not sufficient
case the space in any of the pre- ntinuation of: Box V	
- The inventions of	claims 2-11 do not appear to possess novelty or to involve an inventive
step.	
•	•
	•
•	
	•
	•
•	
	•